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(ECP) and tryptase by UniCAP-FEIA.  Results: NARES and PAR 
presented elevated levels of tryptase, while ECP was mark-
edly increased solely in NARES compared to both the con-
trols and PAR. Elevated levels of IL-1  , IL-17, IFN-  , TNF-  and 
MCP-1 were found in NARES compared to the controls as well 
as PAR. MIP-1  was elevated in NARES and PAR, while IL-4, 
IL-6 and G-CSF showed increased levels in NARES, and IL-
5 was elevated in PAR only.  Conclusions: In patients with NA-
RES and PAR, eosinophils and mast cells appear to be
the pivotal cells of inflammation, reflected by high levels
of tryptase and ECP as well as IL-5 and GM-CSF as factors
for eosinophil migration and survival. The elevated levels
of proinflammatory cytokines in NARES may indicate the 
chronic, self-perpetuating process of inflammation in NARES 
which seems to be more pronounced than in PAR. IL-17 
might be a factor for neutrophilic infiltration or be respon-
sible for remodeling processes in NARES. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Background: Patients with nonallergic rhinitis with eosino-
philia syndrome (NARES) show typical symptoms of persis-
tent allergic rhinitis (PAR). The aim of the present study was 
to compare nasal cytokine patterns between NARES and 
PAR.  Methods: Nasal secretions of 31 patients suffering from 
NARES, 20 patients with PAR to house dust mite and 21 
healthy controls were collected using the cotton wool meth-
od and analyzed for interleukin (IL)-1  , IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-10, IL-12, IL-13, IL-17, granulocyte-macrophage colony-
stimulating factor (GM-CSF), granulocyte colony-stimulat-
ing factor (G-CSF), interferon-  (IFN-  ), tumor necrosis fac-
tor-  (TNF-  ), monocyte chemoattractant protein-1 (MCP-1) 
and macrophage inflammatory protein-1  (MIP-1  ) by Bio-
Plex Cytokine Assay as well as eosinophil cationic protein 
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 Introduction 
 Rhinitis is defined as an inflammation of the nose and 
since markers of inflammation are not routinely exam-
ined in daily practice, the term rhinitis is mainly used for 
a complex of symptoms including rhinorrhea, nasal 
blockage, sneezing and nasal itching  [1] . Compared to 
acute rhinitis that is self-limiting and resolves within 1 or 
2 weeks, chronic rhinitis can persist for several weeks and 
may even be perennially affecting up to 20% of the gen-
eral population  [2] .
 Allergic rhinitis constitutes the most frequent mani-
festation of atopic diseases with nearly 80 million affected 
people in the USA, and thus accounts for about 50% of 
patients with chronic rhinitis  [3] . The classification into 
‘seasonal’ and ‘perennial’ has been replaced by the terms 
‘intermittent’ and ‘persistent’, with persistent meaning 
symptoms occurring  1 4 days a week and  1 4 consecutive 
weeks per year  [2] . The pathogenic features of allergic rhi-
nitis have been explored in many studies. In the early 
phase, the bridging of mast cell-bound allergen-specific 
IgE with allergens leads to the degranulation of mast cells 
and the release of products like histamine and leukotri-
enes. Later, the influx of inflammatory cells like eosino-
phils and basophils leads to persistent inflammation and 
associated tissue changes  [4, 5] .
 As a separate entity of chronic rhinitis, nonallergic 
rhinitis with eosinophilia syndrome (NARES) consti-
tutes a rare nasal condition, although prevalence rates 
range from 2 to 14% among patients with chronic rhinitis 
 [6] . Patients present typical symptoms of persistent rhini-
tis, mainly nasal blockage and rhinorrhea, but in vitro 
and in vivo tests fail to detect any sensitization  [7] . A 
chronic, unspecific liberation of histamine and a self-per-
petuating eosinophilic infiltration have hitherto been 
supposed to be pathogenic factors of this disease, with a 
nasal smear showing more than 25% eosinophilia as a di-
agnostic criterion  [7] . However, recent literature has pro-
vided evidence that some patients with rhinitis show na-
sal allergy with no systemic markers of atopy, either by 
local IgE production or even through an IgE-indepen-
dent antigen-specific pathway  [8, 9] . In addition, it has 
been suggested that this condition may be prevalent in up 
to one third of adults with nonallergic rhinitis, and al-
though it usually occurs as an isolated disorder, there is 
evidence of association with asthma, aspirin sensitivity 
and nasal polyps  [10–13] .
 Investigating cytokine levels and other mediators in 
the nasal fluid of patients with rhinitis has been used in 
a number of studies, either to get more insight of the 
pathogenic conditions  [14] , for diagnostic use  [15] or to 
measure therapeutic effects  [16] .
 The aim of this study was to investigate cytokine levels 
and other inflammatory mediators in the nasal fluid
of patients with persistent allergic rhinitis (PAR) and
NARES in comparison with healthy controls. An attempt 
was made to identify disease-specific cytokine patterns 
and to identify the role of different cytokines in both dis-
eases.
 Methods 
 Study Population 
 Seventy-two adult volunteers (46 males, 26 females, median 
age 32 years, range 15–68 years) participated in this study. Clini-
cal history was taken by one of the investigators. All volunteers 
completed a questionnaire referring to nasal obstruction, rhinor-
rhea, sneezing and nasal itching. Symptoms were rated on a scale 
from 0 to 3 (0 = no symptoms, 1 = minor symptoms, 2 = moderate 
symptoms and 3 = severe symptoms). Patients presenting with 
sensitization to seasonal allergens, a history of bronchial asthma 
and/or bronchial hyperreactivity, chronic rhinosinusitis, nasal 
polyposis or aspirin sensitivity were excluded from the study. Any 
medication taken concerning the nasal disease during or 6 weeks 
prior to the examination also constituted an exclusion criterion, 
especially anti-inflammatory medication such as nasal steroids or 
antihistamines.
 Nasal endoscopy was performed in all participants in order to 
assess clinical signs of rhinitis and to exclude patients with signs 
of purulent rhinitis or polyposis. Allergic rhinitis was determined 
by the patient’s history and by a positive skin prick test (ALK-
Abelló, Wedel, Germany) for the following allergens: timothy 
grass, rye, birch, hazel, alder, beech, mugwort, ribwort, nettle, 
dandelion, house dust mite, storage mite, dog, cat and horse epi-
thelial dander, Alternaria, Aspergillus, Cladosporium and Peni-
cillium. Histamine dihydrochloride solution at 1 mg/ml as a pos-
itive control and allergen-free saline solution as a negative control 
were used. Thereafter specific IgE to the allergens tested posi-
tive in skin prick tests was measured in serum (UniCAP-FEIA, 
Phadia, Freiburg, Germany).
 NARES (n = 31; 5 female, 26 male; median age 31 years, range 
15–68 years) was determined by typical nasal symptoms and neg-
ative skin prick test to all the tested allergens, but with excessive 
levels of eosinophil cationic protein (ECP) in nasal secretions 
( 1 200 ng/ml) in the absence of any other sinonasal disease such 
as polyposis.
 PAR (n = 20; 7 female, 13 male; median age 31 years, range 
17–62 years) due to house dust mites was determined by the pa-
tient’s history, a sensitization to house dust mites with a positive 
skin prick test and a house dust mite-specific IgE (CAP class  6 2), 
and a positive intranasal allergen challenge.
 Healthy controls (n = 21; 14 female, 7 male; median age 36 
years, range 15–66 years) presented no history of nasal com-
plaints, normal ECP levels in nasal secretions and a negative in 
vitro allergy screening test Sx1 (Phadia).
 The study was approved by the local ethics committee and 
written informed consent was obtained from all participants.
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 Biochemical and Immunological Methods 
 Nasal secretions were gained using small cone-shaped cotton 
wool pieces (absorbent cotton, Hartmann Inc., Heidenheim/
Brenz, Germany) with a length of about 3 cm and a diameter of 
about 6 mm. Introduced into the middle meatus of the nose, the 
cotton wool pieces were left in place for 20 min and were subse-
quently centrifuged (+4   °   C, 2,000  g ) on a sieve for 10 min  [15] . 
Control experiments were performed with diluted nasal secre-
tions tested at 1: 2, 1: 5 and 1: 10 for reproducibility and recovery 
rates, which were best at a dilution of 1: 5.
 All samples were analyzed for Interleukin (IL)-1  , IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, granulocyte-mac-
rophage colony-stimulating factor (GM-CSF), granulocyte colo-
ny-stimulating factor (G-CSF), interferon-  (IFN-  ), tumor ne-
crosis factor-  (TNF-  ), monocyte chemoattractant protein-1 
(MCP-1) and macrophage inflammatory protein-1  (MIP-1  ) us-
ing a human cytokine 17-plex panel (Bio-Plex Cytokine Assay, 
Bio-Rad Laboratories, Hercules, Calif., USA). The cytokine assay 
uses fluorescently addressed polystyrene beads with conjugated 
capture antibodies directed to the above-mentioned cytokines. 
After washing, a fluorescently marked detection antibody builds 
an immunoassay with the cytokine. For analysis, two lasers excite 
the fluorochromes: one for classifying each bead, the other for 
quantifying the amount of bound analyte  [10] . Detection levels 
were 0.5 pg/ml.
 Total IgE was measured in nasal secretion diluted 1: 2 (Uni-
CAP-FEIA, Phadia). ECP and tryptase were measured by ELISA 
(UniCAP-FEIA, Phadia). Thresholds for detection were 10 ng/ml 
for ECP and 5 ng/ml for tryptase.
 Statistics 
 SPSS 10.0 software was used for statistical evaluation. Signifi-
cances were obtained by the Kruskal-Wallis one way analysis of 
variance on ranks. When significant differences were indicated, 
the Mann-Whitney U test was also performed. p values  ! 0.05 
were regarded as significant. As values were not normally distrib-
uted, data are given as median and range. Data are shown as box 
plots for graphic presentation of the results with significances 
graphically represented between the corresponding scatter plots.
 Results 
 The clinical characteristics of all patients are given in 
 table 1 . No relevant differences in the clinical appearance 
of PAR and NARES were detectable. As shown in  figure 
1 , a significant difference among the groups could be seen 
in the total IgE in nasal secretion. In PAR total nasal IgE 
(median 4 ng/ml, range 0–145 ng/ml) was significantly 
higher in comparison to the controls (median 0 ng/ml, 
range 0–0 ng/ml, p  ! 0.001) as well as to NARES (median 
0 ng/ml, range 0–83 ng/ml, p  ! 0.05). IgE levels in NARES 
were not significantly elevated.
 Concerning the nasal fluid specimens, ECP showed 
significantly higher levels in NARES (median 472 ng/ml, 
range 241–1,000 ng/ml) compared to PAR (median 72 ng/
ml, range 10–1,000 ng/ml, p  ! 0.001) as well as to healthy 
controls (median 23 ng/ml, range 10–90 ng/ml, p  ! 0.001). 
As shown in  figure 2 , tryptase was significantly elevated 
in PAR (median 14 ng/ml, range 5–1,000 ng/ml, p  ! 0.01) 
compared to the controls (median 5 ng/ml, range 5–16 
ng/ml), and also showed significantly higher levels in 
NARES (median 5 ng/ml, range 5–207 ng/ml, p  ! 0.01).
 For IL-2 (controls: median 0 pg/ml, range 0–12 pg/ml; 
PAR: median 0 pg/ml, range 0–15 pg/ml; NARES: me-
dian 0 pg/ml, range 0–94 pg/ml) and IL-12 (controls: me-
dian 0 pg/ml, range 0–15 pg/ml; PAR: median 0 pg/ml, 
range 0–15 pg/ml; NARES: median 0 pg/ml, range 0–17 
pg/ml), similar levels could be found in the nasal fluids 
of all three groups.
 We detected significantly higher levels of the proin-
flammatory cytokines IL-1  (controls: median 30 pg/ml, 
range 0–412 pg/ml; PAR: median 18 pg/ml, range 3–996 
pg/ml; NARES: median 285 pg/ml, range 41–2,618 pg/ml; 
p  ! 0.001;  fig. 3 ), IFN-  (p  ! 0.001;  table 2 ) and TNF- 
Table 1. M ean symptom scores
Symptom score Controls PAR NARES
Obstruction 0 1.94 1.45
Secretion 0.24 1 1.33
Sneezing 0.38 1 0.81
Itchy nose 0.24 0.8 0.55
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 Fig. 1. Box plot of levels of total IgE in nasal secretions of the three 
patient groups. Total IgE is significantly elevated in PAR versus 
controls ( * * *  p  ! 0.001) as well as versus NARES ( *  p  ! 0.05). 
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 (p  ! 0.001;  table 2 ) in NARES compared to the controls 
and PAR, while there were no significant differences be-
tween levels in PAR and the controls. IL-6 (p  ! 0.001; 
 table  3 ) was significantly elevated in NARES solely in 
comparison to the controls.
 Levels of IL-7 were quite similar in all the groups (con-
trols: median 22 pg/ml, range 7–51 pg/ml; PAR: median 
29 pg/ml, range 12–99 pg/ml; NARES: median 39 pg/ml, 
range 6–196 pg/ml). The magnitude of IL-17 in NARES 
(median 8 pg/ml, range 0–35 pg/ml) was significantly 
higher compared to the controls (median 0 pg/ml, range 
0–22 pg/ml, p  ! 0.01) as well as to PAR (median 0 pg/ml, 
range 0–13 pg/ml, p  ! 0.01;  fig. 4 ).
 IL-8 showed no elevated levels in inter-group compar-
ison, while significantly higher levels of the chemokine 
MCP-1 could be detected in NARES (p  ! 0.01;  table 2 and 
 3 ). MIP-1  was significantly elevated in NARES as well 
as in PAR (p  ! 0.001 and p  ! 0.01, respectively;  table 2 ).
 As shown in  figure 5 , IL-4 was significantly elevated 
in NARES (median 106 pg/ml, range 0–500 pg/ml, p  ! 
0.001) in comparison with the controls (median 0 pg/ml, 
range 0–206 pg/ml) but not versus PAR (median 0 pg/ml, 
range 0–206 pg/ml). The levels of IL-5 in PAR were sig-
nificantly higher compared to the controls (p  ! 0.05), 
while there were no significant differences in levels of IL-
13 in the nasal secretions from all three groups ( table 3 ).
 G-CSF showed significantly elevated levels in NARES 
(median 375 pg/ml, range 0–5,856 pg/ml, p  ! 0.01) com-
pared to the controls (median 53 pg/ml, range 0–2,086 
pg/ml) but not to PAR (median 214 pg/ml, range 0–5,688 
Table 2.  Cytokine levels
IFN- TNF- MCP-1 MIP-1
Controls 26 (0–253) 9 (0–71) 246 (118–388) 136 (18–455)
PAR 49 (0–502) 10 (0–171) 218 (87–523) 259 (73–1,671)
NARES 203 (30–1,129) 62 (11–348) 388 (159–1,022) 378 (121–2,511)
p values
Controls vs. PAR
Controls vs. NARES
PAR vs. NARES
n.s.
<0.001
<0.001
n.s.
<0.001
<0.001
n.s.
<0.01
<0.01
<0.01
<0.001
n.s.
Data are measured as pg/ml and presented as median values with ranges in parentheses. n.s. = Not significant.
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 Fig. 2. Box plot of levels of tryptase in sera of the three patient 
groups. Tryptase is significantly elevated in PAR and NARES ver-
sus controls ( * *  p  ! 0.01). 
 Fig. 3. Box plot of levels of IL-1  in sera of the three patient groups. 
IL-1  is significantly elevated in NARES versus controls as well 
as versus PAR ( * * *  p  ! 0.001). 
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pg/ml). The quantity of GM-CSF was not significantly 
different among the three groups (controls: median 0 pg/
ml, range 0–905 pg/ml; PAR: median 0 pg/ml, range 
0–582 pg/ml; NARES: median 90 pg/ml, range 0–1,176 
pg/ml). IL-10 could not be detected in the controls or 
PAR, but was measurable in a few patients with NARES 
(median 0 pg/ml, range 0–125 pg/ml).
 Discussion 
 Both chronic allergic as well as chronic nonallergic 
rhinitis constitute frequent inflammatory diseases of the 
upper-airway mucosa. Patients suffering from NARES, a 
nonallergic rhinitis defined by nasal mucosa eosinophil-
ia, show symptoms of perennial allergic rhinitis without 
systemic sensitization. Recently, new insights into in-
flammatory processes have become possible by studying 
the release of cytokines and chemokines involved in 
pathogenic pathways. Detecting these mediators in nasal 
fluid has become a standardized and well-evaluated tech-
nique  [11, 15] . However, the results from different studies 
remain inconclusive, particularly regarding the tech-
nique of specimen collection. We used the cotton wool 
method for its accessibility and for prevention of predilu-
tion, which occurs in nasal lavage  [12] .
 Eosinophils are the pivotal cell type in NARES, with 
eosinophilia in the nasal smear as a diagnostic criterion. 
Accordingly, the highest levels of nasal ECP were found 
in patients with NARES. This is in accordance with oth-
Table 3. I nterleukin levels
IL-5 IL-6 IL-8 IL-13
Controls 0 (0–20) 93 (13–1,594) 3,573 (467–23,277) 0 (0–61)
PAR 5 (0–188) 202 (25–750) 4,205 (524–11,759) 0 (0–58)
NARES 0 (0–320) 309 (70–8,168) 3,485 (0–33,932) 13 (0–62)
p values
Controls vs. PAR
Controls vs. NARES
PAR vs. NARES
<0.05
n.s.
n.s.
n.s.
<0.001
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s. 
Data are measured as pg/ml and presented as median values with ranges in parentheses. n.s. = Not significant.
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 Fig. 4. Box plot of levels of IL-17 in sera of the three patient groups. 
IL-17 is significantly elevated in NARES versus controls as well as 
versus PAR ( * *  p  ! 0.01). 
 Fig. 5. Box plot of levels of IL-4 in sera of the three patient groups. 
IL-4 is significantly elevated in NARES versus controls ( * *  p  ! 
0.01). 
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er studies comparing different types of chronic rhinitis 
 [15] . We found even higher levels of ECP in patients with 
sensitization to the perennial allergen house dust mite 
than we had shown in patients with seasonal allergic rhi-
nitis in a previous study (210.2 vs. 115.5 ng/ml)  [14] . This 
might be due to the fact that the nasal fluid of seasonal 
allergic patients was not collected during assured allergen 
exposure. The importance of eosinophils in mucosa in-
flammation in allergic rhinitis has also been highlighted 
in other studies  [13, 17] .
 Tryptase could clearly discriminate the nasal secre-
tions of allergic patients from those of the controls. Mast 
cell activation is one of the main mechanisms in allergic 
rhinitis, which has been proven in former studies  [14, 15] . 
Interestingly, high levels of tryptase were detected in the 
nasal secretions of patients with NARES, which is in ac-
cordance with previous studies showing increased mast 
cells and mast cell activation in different forms of nonal-
lergic rhinitis  [9, 15] . This might also implicate a kind of 
allergen-dependent mast cell activation, either IgE-de-
pendent as suggested in recent challenge studies for local 
allergies  [18] , or IgE-independent as indicated by finding 
free light-chain expression in patients with nonatopic 
rhinitis  [8] .
 For IL-12, which, among other cytokines, is supposed 
to be important in mounting a Th1-helper cell response, 
only low levels were found in all the three groups, sug-
gesting an inferior role of Th1-helper cells in NARES and 
PAR. IL-2, which plays a pivotal role in inflammation and 
stimulates the synthesis of other proinflammatory cyto-
kines like IL-1 or IL-6, showed higher but not significant-
ly elevated level in NARES. Like IL-12, it could not be 
detected in all the samples. Whether this is because of its 
short half-life or the time course in cytokine expression 
cannot be answered conclusively.
 We found a remarkable upregulation of the proin-
flammatory cytokines IL-1  , IL-6, TNF-  and IFN-  in 
NARES in comparison to the controls. Levels of IL-1  , 
TNF-  and IFN-  were also significantly higher com-
pared to PAR. Whilst in PAR IL-1  was 2-fold higher 
than in healthy subjects, a significant increase in com-
parison with the controls was not detected in any of these 
proinflammatory cytokines. Th1-derived, proinflamma-
tory cytokines have often been studied in the nasal secre-
tions of patients with allergic rhinitis, mostly in challenge 
studies  [19] or in seasonal allergic rhinitis  [20, 21] , where 
high levels of IL-1  could mostly be found after challenge 
or during the pollen season. This secretion of IL-1  , 
which activates T lymphocytes and endothelial cells and 
leads to a release of further cytokines, was also detected 
in PAR  [21] , which is in accordance with our findings. 
Measuring proinflammatory cytokines could also be in-
teresting for the detection of a subclinical state of inflam-
mation in patients with seasonal  [21, 22] as well as peren-
nial  [23] allergic rhinitis. In this so called ‘minimal per-
sistent inflammation’  [24] infiltration of neutrophils and 
eosinophils is found without overt allergic symptoms. 
Detecting and treating this state is important, as data 
show a priming effect of the minimally inflamed mucosa 
leading to hyperreactivity of upper and lower airways and 
an increased allergic response  [25] .
 Another interesting finding was the significantly ele-
vated level of IL-17 in NARES. The recent identification 
of an IL-17-producing T helper cell line, Th17 cells, pro-
vided new insight into the development of infectious and 
autoimmune diseases as well as immune responses  [26] . 
IL-17 can enhance human bronchial fibroblast produc-
tion of IL-6, IL-8, and chemokine (C-X-C motif) ligand 1 
(CXCL1) as well as human bronchial epithelial cell ex-
pression of IL-8, CXCL1, chemokine (C-C motif) ligand 
20 (CCL20), intercellular adhesion molecule-1 and G-
CSF  [27, 28] . IL-8 and CXCL1 are potent neutrophil che-
moattractants, whereas IL-6 and G-CSF are important in 
neutrophil maturation. Thus, IL-17 seems to play an im-
portant role in neutrophil activation and proliferation in 
forms of noneosinophilic asthma. Whether or not these 
findings can be transferred to inflammatory processes of 
the nose has not been studied yet. While in our study IL-6 
and G-CSF were significantly elevated in NARES, IL-8 
showed slightly lower levels. On the other hand, MIP-1  , 
a chemoattractant for neutrophil granulocytes as well as 
for eosinophils and basophils, and MCP-1, a chemokine 
for monocytes, were detected in high levels in NARES, 
indicating that not only eosinophils play a role in this in-
flammatory disease. The etiology of neutrophilic infiltra-
tion in nonallergic rhinitis without infection is multifac-
torial, including pollutants and tobacco smoke  [29, 30] . 
As we did not exclude smokers, this cause of neutrophil-
ic infiltration cannot be ruled out. In further studies, na-
sal cytology should be performed to measure different 
cellular patterns, as a high presence of neutrophils could 
lead to resistance to nasal steroids as already shown for 
the lower airways  [31] . Not only Th17 cells can be the 
source of IL-17 as neutrophils, eosinophils, plasma cells 
and serous glands have also been identified  [32, 33] . A re-
cent study by Saitoh et al.  [34] detected IL-17 in the nasal 
polyps of patients with asthma and, besides CD4 T cells, 
could clearly determine eosinophils as the major source 
of IL-17. Moreover, the authors found correlations be-
tween IL-17-positive cells and the eosinophil recruitment 
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into the polyps, epithelial damage and the thickness of 
the basal membrane. This indicates that IL-17 is a deter-
mining factor for mucosal remodeling of nasal polyps be-
ing related to cytotoxic mediators derived from eosino-
phils and/or having a profibrotic capability itself. Some 
investigators even suggest NARES as being a precursor of 
nasal polyps, subsequent asthma or aspirin sensitivity 
 [35] .
 As for Th2-cytokines, we found significantly higher 
levels of IL-4 in NARES compared to the controls, while 
IL-13 showed similar levels in the nasal secretions of all 
groups. IL-4 was insignificantly elevated in patients with 
PAR. Although both cytokines are key mediators in al-
lergic inflammation  [36] and should therefore be elevated 
in PAR, these results are in accordance with previous 
findings showing elevated levels of IL-4 in the nasal se-
cretions of patients with allergic rhinitis  [37, 38] but no 
elevation of IL-13  [13] . IL-5 was significantly elevated in 
PAR and to a similar extent also in NARES. It activates 
the selective migration of eosinophils from the periph-
eral circulation into tissues and constitutes a major sur-
vival factor for eosinophils  [39] being the only human 
leukocytes expressing a specific IL-5 receptor  [40] . The 
interesting finding of high amounts of Th2 cytokines 
IL-4 and IL-5 in NARES cannot be explained yet. As we 
could detect IgE in the nasal secretions of about 20% of 
NARES subjects, it cannot be ruled out that in a small 
subgroup of NARES patients a local nasal allergic disease 
pathway may be present. However, this cannot sufficient-
ly explain the more general characteristics of our find-
ings. Therefore, further work is necessary to confirm 
these results.
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